Awiqli (Insulin Icodec-Abae) is a next-generation, ultra-long-acting basal insulin developed by Novo Nordisk for the treatment of adults with Type 2 Diabetes Mellitus. Designed for once-weekly administration, insulin icodec-abæ forms a stable subcutaneous depot and binds reversibly to albumin, enabling slow, continuous insulin release over an extended period.

This unique pharmacokinetic profile helps maintain consistent glycemic control while significantly reducing injection frequency compared to traditional daily basal insulins. Approved in March 2026, Awiqli represents a major advancement in diabetes care, with the potential to improve patient adherence, simplify treatment regimens, and deliver sustained glucose-lowering efficacy.